38.45 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||37.70 x 100|
|Ask||41.99 x 500|
|Day's Range||37.28 - 40.35|
|52 Week Range||27.00 - 57.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.25|
An East Bay biotech company, attempting to find next-generation ways to stimulate the immune system to fight cancer, raised $120 million in an upsized initial public offering. The IPO from Hayward's Arcus Biosciences Inc. (RCUS) priced at $15 — at the high end of the company's range — as it increased the number of shares available from 7.1 million to 8 million. It is the third IPO among Bay Area life sciences companies this year.
More top pharmaceutical executives are trying their hand at running biotech startups, a trend that could pay dividends for venture capitalists.
A pair of IPOs from Bay Area companies are expected at the end of the week from Zscaler Inc. and Arcus Biosciences Inc. The one from San Jose-based cloud security company Zscaler is expected Friday and would be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) went public. The offering from Arcus Biosciences is the third from a Bay Area biotech, following two at the end of January from Redwood City companies ARMO Biosciences Inc. (ARMO) and Menlo Therapeutics Inc. (MNLO).
The targets have been raised again for what's expected to be the first Bay Area tech IPO in four months. San Jose-based Zscaler Inc. increased the amount of stock for sale and the price targets on its offer, boosting how much it could raise to about $207 million, up 50 percent. It was valued by private investors at a little over $1 billion when it raised its last venture round in the summer of 2015.
Friday's offering from San Jose-based cloud security company Zscaler is set to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix went public.
Cloud security unicorn Zscaler Inc. set a price range for its upcoming IPO that would raise up to about $138 million and boost its valuation by about 40 percent. The San Jose company would be valued at around $1.4 billion at the high end of its proposed price range of between $10 and $12 a share. It's in line to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) raised $120 million.
Cloud security unicorn Zscaler Inc. is the most likely candidate to end the Bay Area's latest tech IPO drought. There were only six tech IPOs from the region last year that raised more than $100 million. Uncertainties over the massive tax overhaul and disappointing Wall Street debuts from technology unicorns Snap and Blue Apron were blamed for keeping Valley IPOs down last year, along with IPO-sized late stage funding rounds from investors like Softbank.
Late-stage immuno-oncology company ARMO Biosciences Inc (NASDAQ: ARMO ) recently went public last month, offering 7.53 million shares at $17 each. The IPO was priced on Jan. 26. The Analyst After the expiration ...
What: ARMO BioSciences, Inc., a late-stage immuno-oncology company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Peter Van Vlasselaer, PhD, Founder, President and Chief Executive ...
CFO software developer Adaptive Insights Inc. is reportedly lining up an IPO. The Palo Alto-based business has hired Morgan Stanley to lead the offering, Reuters said it was told by unnamed sources. Adaptive Insights was launched by Robert Hull in 2003 to build a cloud-based software platform that chief financial officers can use for budgeting, forecasting, reporting, consolidation, dashboards and analytics aimed at finance, sales and other business enterprises.
The potential for mergers and acquisitions in biopharma—driven by the new business-friendly tax package—is fueling investor enthusiasm for biotech IPOs.
After a strong run of IPOs in 2017, venture-backed ARMO BioSciences Inc., resTORbio Inc., and Solid Biosciences were the latest to join a parade of solid offerings.
REDWOOD CITY, Calif. , Jan. 25, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. ("ARMO"), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 ...